Overland Park Regional Medical Center Extends Leadership in

ST. LOUIS, Sept. 13, 2022 (GLOBE NEWSWIRE) — Stereotaxis (NYSE: STXS), a pioneer and world chief in surgical robotics for minimally invasive endovascular intervention, as we speak introduced that Overland Park Regional Medical Center (OPRMC) is establishing its second robotic program for the remedy of coronary heart rhythm issues.

OPRMC, part of HCA Midwest Health, first established a robotic coronary heart rhythm care program in 2019. Since then, it has constructed a number one observe that applies superior robotic expertise to deal with a broad vary of arrhythmias, together with these usually thought-about too difficult for conventional approaches. OPRMC is now among the many first in the nation to undertake the Genesis Robotic Magnetic Navigation system, the newest advance in robotic expertise and can turn out to be the primary hospital in the U.S. to double its capability for robotic cardiac ablation with two Stereotaxis programs for sufferers receiving minimally invasive cardiac ablation procedures.

“The Kansas City Heart Rhythm Institute at OPRMC has successfully built a reputation for leadership in clinical care and healthcare research. Our robotic electrophysiology program has been an important pillar in that success,” stated Dr. Dhanunjaya Lakkireddy, Executive Medical Director for the Kansas City Heart Rhythm Institute. “We are excited to bring the latest robotic technology to our community.”

Robotic Magnetic Navigation introduces the advantages of robotic precision and security to cardiac ablation, a standard minimally invasive process to deal with arrhythmias. Tens of hundreds of thousands of people worldwide endure from arrhythmias – irregular coronary heart rhythms that consequence when the center beats too rapidly, too slowly, or with an irregular sample. When left untreated, arrhythmias might considerably enhance the chance of stroke, coronary heart failure, and sudden cardiac arrest.

“We are delighted to expand our partnership with Dr. Lakkireddy and Overland Park Regional Medical Center as they improve patient care, advance clinical science, and continue to grow a leading arrhythmia care program in Kansas City,” stated David Fischel, Chairman and CEO of Stereotaxis.

About Stereotaxis
Stereotaxis is the worldwide chief in progressive robotic applied sciences designed to reinforce the remedy of arrhythmias and carry out endovascular procedures. Its mission is the invention, improvement and supply of robotic programs, devices, and data options for the interventional laboratory. These improvements assist physicians present unsurpassed affected person care with robotic precision and security, increase entry to minimally invasive remedy, and improve the productiveness, connectivity, and intelligence in the working room. Stereotaxis expertise has been used to deal with over 100,000 sufferers throughout the United States, Europe, Asia, and elsewhere. For extra info, please go to www.stereotaxis.com.

This press launch consists of statements that will represent “forward-looking” statements, normally containing the phrases “believe”, “estimate”, “project”, “anticipate” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company’s control and may be revised, modified, delayed, or canceled.